Tumor vaccine with IL-33 (interleukin-33) used as therapeutic target

A technology of interleukin and anti-tumor immunity, applied in the field of breast cancer vaccines, can solve problems such as threats to women's life and health and patient death

Pending Publication Date: 2017-05-10
INST OF MEDICAL BIOLOGY CHINESE ACAD OF MEDICAL SCI
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] Breast cancer is one of the most common malignant tumors in women, and its mortality rate has risen to the first among female malignant tumors, seriously threatening women's life and health. At present, with the development of medical technology and the application of auxiliary methods such as radiotherapy and chemotherapy , the overall survival rate of breast cancer patients has been greatly improved, but there are still 30%-40% recurrence and metastasis every year, which still lead to the death of patients

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Tumor vaccine with IL-33 (interleukin-33) used as therapeutic target
  • Tumor vaccine with IL-33 (interleukin-33) used as therapeutic target
  • Tumor vaccine with IL-33 (interleukin-33) used as therapeutic target

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0017] Example 1: Induced expression and purification of HBcAg-33

[0018] The induced expression and purification methods of HBcAg-33 are as described in the patent > (ZL 2014 1 0248884.2). According to the steps of this method, HBcAg-33 VLPs and carrier HBcAg VLPs were obtained as immunogens for subsequent experiments.

Embodiment 2

[0019] Example 2: Preventive immunization strategy for mice

[0020] Balb / c female mice at 6-8 weeks were randomly divided into 3 groups, 8 rats / group, which were vaccine group, vehicle group and PBS group respectively. Immunization forms such as figure 1 As shown, the purified HBcAg-33 VLPs, carrier HBcAg VLPs, and PBS were subcutaneously immunized on the back of the corresponding group respectively, and each animal was immunized once every two weeks at an injection dose of 100ug, for a total of 3 times. One week after each immunization, blood was collected from the saphenous vein of the thigh of the mice to detect the antibody level. Such as figure 2 As shown, the antibody titer can reach up to 409600.

Embodiment 3

[0021] Example 3: Establishment of an orthotopic model of mouse breast cancer:

[0022] First, in RPMI-1640 medium containing 10% FBS, 1% penicillin and streptomycin mixed solution, at 37°C, 5% CO 2 4T1 tumor cells were cultured in the incubator, and 4T1 tumor cells were injected into the fourth abdominal fat pad of mice every two weeks after the last immunization, 1×10 per mouse. 5 cell, the tumor was formed on the 10th day, the tumor was measured every two days, the tumor growth curve was drawn, and the tumor growth was monitored. image 3 shown.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
antibody titeraaaaaaaaaa
Login to view more

Abstract

The invention relates to the field of molecular biology and immunology. Specifically, active immunity intervention is performed on a mouse with virus-like particles presenting IL-33 (interleukin-33) whole protein to induce the organism to produce specific IgG antibody response resistant to IL-33, so that the expression level of IL-33 in the mouse is decreased continuously, the anti-tumor immunity response of the organism is enhanced, and tumor growth is inhibited.

Description

technical field [0001] The invention relates to the fields of molecular biology and immunology, in particular to a breast cancer vaccine with interleukin-33 as a therapeutic target. Background technique [0002] Interleukin-33 is a member of the IL-1 family discovered by Schmitz et al. in 2005. It is mainly expressed constitutively in some barrier cells and released when cells are necrotic or damaged, so it is called "alarm hormone". IL-33 can bind to ST2 receptors expressed on the surface of Th2 cells such as macrophages, DC cells, and NK cells, activate downstream signaling pathways, and regulate innate and adaptive immunity. In addition, under specific pathological conditions, IL-33 can also activate Th1, CD8 + Immune cells such as T cells. IL-33 has a dual role in inflammatory diseases. On the one hand, it has a protective effect on obesity and atherosclerosis, and on the other hand, it has an inflammatory effect in asthma and allergic diseases. [0003] The role of...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/00A61P35/00
CPCA61K39/0011
Inventor 马雁冰冯雪军刘红仙褚晓杰黄惟巍
Owner INST OF MEDICAL BIOLOGY CHINESE ACAD OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap